Clinical Trials Logo

Hepatobiliary Disorders clinical trials

View clinical trials related to Hepatobiliary Disorders.

Filter by:
  • None
  • Page 1

NCT ID: NCT06468787 Completed - GYN Disorders Clinical Trials

Kosmos Anatomical Object Labeling and View Identification Pivotal Study

Start date: February 7, 2024
Phase: N/A
Study type: Interventional

This is a multi-site, multi-group study that obtained two sets of ultrasound scans from all enrolled participants. Participants underwent limited ultrasound scanning by both cardiac sonographers and abdominal sonographers. Algorithm's performance on the view identification task and the object labeling task is computed.

NCT ID: NCT05481398 Completed - Clinical trials for Surgical Site Infection

A Randomized Controlled Trial Evaluating the Role of Negative Pressure Wound Therapy (NPWT) for Incisional Surgical Site Infections in Patients Undergoing Hepatopancreatobiliary Surgery

NPWT
Start date: March 6, 2021
Phase: N/A
Study type: Interventional

To compare the rates of incisional surgical site infections (iSSIs) within 7 days of hepatopancreatobiliary (HPB) surgery using negative pressure wound therapy (NWPT) versus using standard sterile gauze dressing.

NCT ID: NCT03357380 Completed - Clinical trials for Non-alcoholic Fatty Liver Disease

A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver

Start date: November 28, 2017
Phase: Phase 1
Study type: Interventional

This study is looking at the effect of semaglutide on subjects with nonalcoholic fatty liver disease.This study is comparing the change in early stages of scar tissue in the liver and fat deposition in the liver in people taking semaglutide and placebo (a dummy medicine). Participants will either get semaglutide or placebo; which treatment participants get is decided by chance. Semaglutide is a medicine under clinical investigation. That means that the medicine has not yet been approved by the authorities. Participants will need to self-inject medicine once daily for 72 weeks. The medicine should be injected under the skin in the stomach, thigh or upper arm. There are about 3 weeks before participants start the study medicine and 7 weeks after you stop it. The study will last for about 82 weeks in total. Participants will have 12 clinic visits, 6 phone calls and 4 visits to an MRI centre. The study includes MRI scans of the stomach. The MRI scans will take place at a different location. Participants will be excluded from the study if the study doctor thinks that there are risks for participants health. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

NCT ID: NCT02970942 Completed - Clinical trials for Non-alcoholic Steatohepatitis

Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

Start date: November 30, 2016
Phase: Phase 2
Study type: Interventional

Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis